Diagnostic validity of specific immunoglobulin E levels to alpha-gal in alpha-gal syndrome: a cross-sectional analysis.
Alpha-gal syndrome
Diagnostic validity
Food allergy
Specific immunoglobulin E
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
11
06
2023
accepted:
06
11
2023
medline:
1
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
The diagnosis of Alpha-gal Syndrome (AGS) is based on the presence of symptoms after being exposed to potential sources of alpha-gal together with values of specific IgE (sIgE) to alpha-gal ≥ 0.1 kUA/L or ≥ 0.35 kUA/L. The aim of this study was to evaluate the diagnostic validity of sIgE levels to alpha-gal ≥ 0.1 kUA/L for identifying AGS. This was a cross-sectional analysis of adult patients with available data on sIgE levels to alpha-gal, classified into two groups according to the presence (Group 1) or absence (Group 2) of symptoms after being exposed to potential sources of alpha-gal. Values of sIgE to alpha-gal ≥ 0.1 kUA/l were considered a positive result. A descriptive analysis of internal and external validity parameters was performed in the entire population and adjusted by sex. The study included 33 individuals in Group 1 and 65 in Group 2, with a mean age of around 47 years. The analysis of internal validity parameters revealed a high sensitivity, specificity, and positive probability ratio, with higher sensitivity in men and higher specificity in women. The analysis of external validity parameters showed a high negative predictive value and global value in all populations and both sexes. However, the positive predictive value was relatively high in men, but low in women. Our results suggest that sIgE levels ≥ 0.1 kUA/L may be a useful tool for the diagnosis of AGS, although other factors and diagnostic techniques should also be considered.
Sections du résumé
BACKGROUND
BACKGROUND
The diagnosis of Alpha-gal Syndrome (AGS) is based on the presence of symptoms after being exposed to potential sources of alpha-gal together with values of specific IgE (sIgE) to alpha-gal ≥ 0.1 kUA/L or ≥ 0.35 kUA/L. The aim of this study was to evaluate the diagnostic validity of sIgE levels to alpha-gal ≥ 0.1 kUA/L for identifying AGS.
METHODS
METHODS
This was a cross-sectional analysis of adult patients with available data on sIgE levels to alpha-gal, classified into two groups according to the presence (Group 1) or absence (Group 2) of symptoms after being exposed to potential sources of alpha-gal. Values of sIgE to alpha-gal ≥ 0.1 kUA/l were considered a positive result. A descriptive analysis of internal and external validity parameters was performed in the entire population and adjusted by sex.
RESULTS
RESULTS
The study included 33 individuals in Group 1 and 65 in Group 2, with a mean age of around 47 years. The analysis of internal validity parameters revealed a high sensitivity, specificity, and positive probability ratio, with higher sensitivity in men and higher specificity in women. The analysis of external validity parameters showed a high negative predictive value and global value in all populations and both sexes. However, the positive predictive value was relatively high in men, but low in women.
CONCLUSIONS
CONCLUSIONS
Our results suggest that sIgE levels ≥ 0.1 kUA/L may be a useful tool for the diagnosis of AGS, although other factors and diagnostic techniques should also be considered.
Identifiants
pubmed: 38037176
doi: 10.1186/s13223-023-00856-6
pii: 10.1186/s13223-023-00856-6
pmc: PMC10691071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102Informations de copyright
© 2023. The Author(s).
Références
Ticks Tick Borne Dis. 2021 May;12(3):101674
pubmed: 33529984
Prim Care Respir J. 2006 Aug;15(4):228-36
pubmed: 16839813
Clin Exp Allergy. 2015 Oct;45(10):1483-96
pubmed: 26215729
Pediatr Allergy Immunol. 2018 Dec;29(8):841-849
pubmed: 30144162
J Asthma Allergy. 2022 Jul 18;15:957-970
pubmed: 35879928
Clin Exp Allergy. 2001 Sep;31(9):1464-9
pubmed: 11591198
Allergy. 2018 May;73(5):1131-1134
pubmed: 29161766
Ann Allergy Asthma Immunol. 2019 Jun;122(6):598-602
pubmed: 30922956
Pediatr Allergy Immunol. 2021 Feb;32(2):223-233
pubmed: 33020989
J Allergy Clin Immunol Pract. 2020 Jan;8(1):15-23.e1
pubmed: 31568928
J Allergy Clin Immunol. 2017 Aug;140(2):608-610.e5
pubmed: 28279684
Expert Rev Mol Diagn. 2020 Sep;20(9):905-911
pubmed: 32628573
Ann Allergy Asthma Immunol. 2021 Apr;126(4):411-416.e1
pubmed: 33422649
Ann Allergy Asthma Immunol. 2018 Oct;121(4):509-511
pubmed: 29966704
Clin Transl Allergy. 2021 Dec 15;11(10):e12087
pubmed: 34938441
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2348-2358.e4
pubmed: 30940532
Expert Rev Clin Immunol. 2020 Jul;16(7):667-677
pubmed: 32571129
Curr Opin Pediatr. 2020 Dec;32(6):816-824
pubmed: 33009122
J Investig Allergol Clin Immunol. 2019;29(6):436-443
pubmed: 30676319